ITOS - iTeos Therapeutics, Inc. Stock Price, Fair Value and News

$10.15+0.02 (+0.20%)

Market Closed as of 28 Aug 2025, 04:00 pm ET

ITOS Stock Valuation Analysis

Valuation

Max Portfolio %

ITOS Price Action

ITOS RSI Chart

ITOS Stock Valuation Analysis

Valuation

Max Portfolio %

ITOS Valuation

ITOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ITOS Fundamentals

ITOS Revenue

ITOS Earnings

ITOS Profitability

ITOS Investor Care

Revenue & Growth

How iTeos Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2024	-	35.0M	35.0M	35.0M
2023	127.7M	86.0M	66.5M	12.6M
2022	500.0M	539.0M	454.2M	267.6M
2021	9.0M	10.6M	112.6M	352.4M
2020	4.4M	4.8M	5.2M	5.6M
2019	-	-	-	4.0M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Michel Detheux Ph.D.
WEBSITE	iteostherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	125